AbbVie (ABBV) Launches Boey In Europe With A Different Take On Wrinkle Injectables

• Allergan Aesthetics, an AbbVie company, received European approval for Boey, a botulinum toxin serotype E injectable for glabellar lines.
• Boey is described as a first in its class in Europe, with rapid onset and short duration properties that differ from existing neurotoxin options.
• The launch expands AbbVie’s aesthetics portfolio, an important focus area for NYSE:ABBV following the loss of Humira exclusivity.

For AbbVie, aesthetics sit alongside immunology and oncology as a core business line, and Allergan Aesthetics is central to that effort. The introduction of Boey adds a differentiated product profile within facial injectables, where treatment duration and onset speed are key points of comparison for both physicians and patients. This development comes as the aesthetics industry continues to see demand tied to discretionary procedures and a growing mix of minimally invasive treatments.

For investors following NYSE:ABBV, Boey’s approval in Europe illustrates how the company is adding new products in areas that management has identified as important for its strategy. The commercial roll out, physician adoption, and any follow on regulatory decisions in other regions are likely to be areas worth watching as the aesthetics business evolves within AbbVie’s broader portfolio.

Stay updated on the most important news stories for AbbVie by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on AbbVie.

We've flagged 4 risks for AbbVie. See which could impact your investment.

Quick Assessment

• ⚖️ Price vs Analyst Target: AbbVie trades at US$256.91, about 4.1% below the US$267.79 analyst target, which sits comfortably inside the US$200 to US$328 range.
• ✅ Simply Wall St Valuation: The stock is flagged as undervalued, trading about 44.7% below an internal fair value estimate.
• ✅ Recent Momentum: A 1.4% return over the last 30 days indicates slightly positive recent momentum into the Boey launch.

There's only one way to know the right time to buy, sell or hold AbbVie. Head to Simply Wall St's company report for the latest analysis of AbbVie's Fair Value.

Key Considerations

• 📊 The European approval of Boey broadens AbbVie’s aesthetics lineup, adding a differentiated rapid onset option that aligns with its focus on immunology, oncology and aesthetics.
• 📊 Watch how quickly physicians adopt Boey, any pricing disclosures, and whether management starts quantifying aesthetics contributions alongside the current P/E of 126.3x and forward P/E of 29.6x.
• ⚠️ Simply Wall St flags four minor risks including high debt and dividend coverage, so investors may want to weigh new product momentum against balance sheet and payout pressures.

Dig Deeper

For the full picture including more risks and rewards, check out the complete AbbVie analysis. Alternatively, you can check out the community page for AbbVie to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com